<DOC>
	<DOCNO>NCT00074087</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposomal doxorubicin , use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness liposomal doxorubicin treat patient stage IIB , stage IVA , stage IVB recurrent refractory mycosis fungoides .</brief_summary>
	<brief_title>Liposomal Doxorubicin Treating Patients With Stage IIB , Stage IVA , Stage IVB Recurrent Refractory Mycosis Fungoides</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine antitumor activity doxorubicin HCl liposome , term response rate ( complete response partial response ) , patient stage IIB , IVA , IVB recurrent refractory mycosis fungoides . Secondary - Determine time progression duration response patient treated drug . - Determine toxicity drug patient . OUTLINE : This open-label , nonrandomized , multicenter study . Patients receive doxorubicin HCl liposome IV 1 hour day 1 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity maximum cumulative anthracycline ( ) dose 400 mg/m^2 reach ( include anthracyclines prior treatment ) . Patients follow every 12 week disease progression . PROJECTED ACCRUAL : A total 48 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mycosis fungoides Stage IIB , IVA , IVB Refractory recurrent disease least 2 follow prior therapy : Local and/or systemic steroid Retinoids Interferon alfa Local carmustine Systemic chemotherapy Psoralen ultraviolet A ( PUVA ) light therapy No CNS involvement No erythroderma ( T4 ) PATIENT CHARACTERISTICS : Age Over 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Neutrophil count least 1,500/mm^3 WBC least 2,000/mm^3 Platelet count least 75,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal Creatinine great 1.5 time ULN Cardiovascular LVEF normal echocardiography radionuclide angiocardiography Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 2 year study participation No psychological , familial , sociological , geographical condition would preclude study compliance followup No active infection require specific therapy ( e.g. , antibiotic antiHIV therapy ) No prior concurrent primary malignant tumor except adequately treat carcinoma situ cervix squamous cell basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics More 2 week since prior immunotherapy Chemotherapy See Disease Characteristics Prior systemic chemotherapy allow provide follow condition meet : Cumulative anthracycline dose le 200 mg/m^2 No allergy anthracyclines Prior methotrexate low dose ( i.e. , weekly dose less 30 mg ) More 2 week since prior chemotherapy Endocrine therapy See Disease Characteristics No concurrent systemic steroid Radiotherapy More 2 week since prior radiotherapy Surgery Not specify Other Recovered toxic effect prior therapy , exclude alopecia No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>